News articles about Entellus Medical (NASDAQ:ENTL) have trended positive this week, Accern Sentiment reports. The research firm ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Entellus Medical earned a media sentiment score of 0.26 on Accern’s scale. Accern also gave news articles about the medical technology company an impact score of 45.7457387117323 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
A number of analysts have commented on ENTL shares. ValuEngine upgraded shares of Entellus Medical from a “sell” rating to a “hold” rating in a research report on Thursday, December 7th. William Blair downgraded shares of Entellus Medical from an “outperform” rating to a “market perform” rating in a research report on Friday, December 8th. TheStreet upgraded shares of Entellus Medical from a “d” rating to a “c-” rating in a research report on Thursday, December 14th. Zacks Investment Research downgraded shares of Entellus Medical from a “hold” rating to a “sell” rating in a research report on Wednesday, January 3rd. Finally, BidaskClub downgraded shares of Entellus Medical from a “sell” rating to a “strong sell” rating in a research report on Tuesday, January 16th. Two analysts have rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $20.33.
Entellus Medical (ENTL) traded down $0.01 during midday trading on Tuesday, hitting $24.00. 43,800 shares of the company were exchanged, compared to its average volume of 178,331. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.92 and a quick ratio of 1.71. Entellus Medical has a twelve month low of $11.47 and a twelve month high of $25.58. The company has a market cap of $611.38, a P/E ratio of -18.75 and a beta of -0.02.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by BBNS and is owned by of BBNS. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://baseballnewssource.com/2018/03/13/entellus-medical-entl-receives-daily-news-sentiment-score-of-0-26/2024018.html.
About Entellus Medical
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
Receive News & Ratings for Entellus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical and related companies with MarketBeat.com's FREE daily email newsletter.